Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- None.
- None.
A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on treatments for viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103111932/en/
Media and Investors
Jennifer Viera
617-744-3848
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
FAQ
What is the event Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) will be presenting at?
When will the presentation take place?
Where will the presentation be held?
How can I access the live webcast of the event?